中华全科医师杂志
中華全科醫師雜誌
중화전과의사잡지
CHINESE JOURNAL OF GENERAL PRACTITIONERS
2010年
8期
536-539
,共4页
罗波%孙立江%刘鹏%郝建波%宋保连%张劲峰
囉波%孫立江%劉鵬%郝建波%宋保連%張勁峰
라파%손립강%류붕%학건파%송보련%장경봉
肿瘤转移%骨%二膦酸盐类%前列腺肿瘤%疼痛
腫瘤轉移%骨%二膦痠鹽類%前列腺腫瘤%疼痛
종류전이%골%이련산염류%전렬선종류%동통
Neoplasm metastasis%Bone%Bisphosphonates%Prostatic neoplasms%Pain
目的 了解大剂量帕米膦酸二钠治疗前列腺癌骨转移疼痛的疗效及安全性.方法 将100例确诊为前列腺癌骨转移并伴骨痛的患者分为大剂量组、常规剂量组(各50例),各组分别静脉滴注不同剂量帕米膦酸二钠,大剂量组为第1天90 mg、第2天60 mg,常规剂量组为第1天60 mg、第2天30 mg,每4周重复,共2个周期.观察患者治疗前后疼痛、活动能力、生存质量变化和不良反应情况.结果 治疗后大剂量组的有效止痛率86%(43/50),明显高于常规剂量组的42%(21/50),差异有统计学意义(χ2=22.79,P＜0.01);两组活动能力改善分别为39例(87%)和21例(46%),生存质量改善分别为33例(66%)和18例(36%),差异均有统计学意义(χ2值分别为17.04和9.00,均P＜0.01).均无近期严重不良反应.结论 大剂量帕米膦酸二钠可缓解前列腺癌骨转移所致疼痛,改善患者生存质量.
目的 瞭解大劑量帕米膦痠二鈉治療前列腺癌骨轉移疼痛的療效及安全性.方法 將100例確診為前列腺癌骨轉移併伴骨痛的患者分為大劑量組、常規劑量組(各50例),各組分彆靜脈滴註不同劑量帕米膦痠二鈉,大劑量組為第1天90 mg、第2天60 mg,常規劑量組為第1天60 mg、第2天30 mg,每4週重複,共2箇週期.觀察患者治療前後疼痛、活動能力、生存質量變化和不良反應情況.結果 治療後大劑量組的有效止痛率86%(43/50),明顯高于常規劑量組的42%(21/50),差異有統計學意義(χ2=22.79,P＜0.01);兩組活動能力改善分彆為39例(87%)和21例(46%),生存質量改善分彆為33例(66%)和18例(36%),差異均有統計學意義(χ2值分彆為17.04和9.00,均P＜0.01).均無近期嚴重不良反應.結論 大劑量帕米膦痠二鈉可緩解前列腺癌骨轉移所緻疼痛,改善患者生存質量.
목적 료해대제량파미련산이납치료전렬선암골전이동통적료효급안전성.방법 장100례학진위전렬선암골전이병반골통적환자분위대제량조、상규제량조(각50례),각조분별정맥적주불동제량파미련산이납,대제량조위제1천90 mg、제2천60 mg,상규제량조위제1천60 mg、제2천30 mg,매4주중복,공2개주기.관찰환자치료전후동통、활동능력、생존질량변화화불량반응정황.결과 치료후대제량조적유효지통솔86%(43/50),명현고우상규제량조적42%(21/50),차이유통계학의의(χ2=22.79,P＜0.01);량조활동능력개선분별위39례(87%)화21례(46%),생존질량개선분별위33례(66%)화18례(36%),차이균유통계학의의(χ2치분별위17.04화9.00,균P＜0.01).균무근기엄중불량반응.결론 대제량파미련산이납가완해전렬선암골전이소치동통,개선환자생존질량.
Objective To study efficacy and safety of large dose of pamidronate disodium in treatment for patients with painful bone metastasis of prostate cancer. Methods A total of 100 patients with painful bone metastasis of prostate cancer were randomized into large dose group and conventional dose group, with 50 cases each. Pamidronate disodium was administered by intravenous infusion, 90 mg on the first day and 60 mg on the second day for large dose group, and 60 mg on the first day and 30 mg on the second day for conventional dose group, respectively, every 4 weeks for two courses. Changes of pain,mobility, quality of life and adverse effect in patients before and after treatment were observed. Results After treatment, pain was relieved in 43 of 50 patients ( 86% ) in large dose group, significantly more than that in conventional dose group (21/50, 42% ) (χ2 = 22.79, P ＜ 0. 01 ). Both mobility and quality of life were improved in 39 and 33 patients ( 87% and 66% ), respectively in large dose group and 21 and 18 (46% and 36% ), respectively in conventional dose group (χ2 = 17.04 and 9. 00, P ＜0. 01 ). No severe adverse effect in both groups was observed. Conclusions Pain in patients with bone metastasis of prostate cancer can be significantly relieved with large dose of pamidronate disodium, as well as their quality of life improved.
